Faron Pharmaceuticals Presents Melanoma Trial Results at ESMO Congress
What happened
Faron Pharmaceuticals announced final results from the metastatic melanoma cohort of its Phase 1/2 MATINS study at the European Society for Medical Oncology Congress 2026. The study involved 25 patients with checkpoint inhibitor-refractory metastatic melanoma who received single-agent bexmarilimab. The disease control rate was 20%, and the median overall survival was 7.6 months.
From investegate.co.uk
Why it matters
The presentation provides complete survival data for all 25 patients in the melanoma cohort, offering insight into the efficacy of bexmarilimab in patients who have failed prior anti-PD-1 and anti-CTLA-4 therapies. This research contributes to the understanding of treatment options for advanced metastatic melanoma.
From investegate.co.uk
Who's involved
- European Society for Medical OncologyHosted the Congress where the clinical data was presented
Keep exploring
The entities involved
-
European Society for Medical Oncology
Professional organisation
Related events
- Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.
- Study results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.